"Knowing that the small cell transformations happen allows us to better and more accurately treat people. And then I think, perhaps most importantly, is that there's incredible interest and efforts going on in the lung cancer research community to develop better treatment options for either small cell diagnosed upfront or transform small cell with lots of clinical trials ongoing."
Learn about the latest research on how non-small cell lung cancer can transform into small cell lung cancer and how that can impact treatment options from Jacob Berchuck, MD, Board-Certified Medical Oncologist at Emory University in this Expert Speaker video from December 11, 2024.
This video was recorded during the LiveLung Virtual Lung Cancer meeting December 11, 2024.
Subscribe to our YouTube channel and click the notification bell so you know when new educational lung cancer videos are available https://www.youtube.com/livelung
About the Speaker Dr. Jacob Berchuck is a board certified Medical Oncologist and Assistant Professor in the Department of Hematology and Medical Oncology at Emory University and the Winship Cancer Institute.
Dr. Berchuck earned his undergraduate and medical degrees at Duke University. He trained in Internal Medicine at the University of California San Francisco (UCSF) Medical Center and completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Berchuck also received his post-doctoral research training in cancer epigenetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute. Prior to joining Emory University, Dr. Berchuck served as an Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at the Dana-Farber Cancer Institute and Brigham and Women's Hospital.
In addition to caring for patients with prostate and testicular cancer at the Winship Cancer Institute, Dr. Berchuck leads a translational research lab focused on pioneering advances that transform how we manage and treat individuals living with cancer. Core objectives of Dr. Berchuck’s research include developing biomarkers to guide treatment decisions, deciphering mechanisms of treatment resistance, and discovering novel therapeutic strategies. His research predominantly focuses on “liquid biopsies” – studying tumor biology by profiling cell-free DNA circulating in the bloodstream – working towards a future where a simple blood draw can enable real-time insights to choose the right treatment for the right patient at the right time. Dr. Berchuck’s research has been published in several high impact journals, including Nature Medicine, Cancer Cell, Annals of Oncology, JAMA Oncology, European Urology, Clinical Cancer Research, Cancer Research, and others.
This Video Content has been made available for informational and educational purposes only. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.
LiveLung and speakers hereby disclaim any and all liability to any party for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising directly or indirectly from any use of the Video Content, which is provided as is, and without warranties.